Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Laura Michaelis MD

Laura Michaelis MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology
Program: Bone Marrow Transplant

Member of the Cancer Center


  • Hematopoietic stem cell transplantation in older persons: respecting the heterogeneity of age. (Michaelis LC, Hamadani M, Hari PN) Expert Rev Hematol 2014 Jun;7(3):321-4 PMID: 24785114 05/03/2014
  • Cutis verticis gyrata. (Walshauser MA, Birch NW, Michaelis LC) Am J Med Sci 2014 Aug;348(2):176 PMID: 23328837 01/19/2013
  • Salvage second hematopoietic cell transplantation in myeloma. (Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2013 May;19(5):760-6 PMID: 23298856 PMCID: PMC3816739 01/10/2013
  • Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. (Stein BL, Saraf S, Sobol U, Halpern A, Shammo J, Rondelli D, Michaelis L, Odenike O, Rademaker A, Zakarija A, McMahon B, Spivak JL, Moliterno AR) Leuk Lymphoma 2013 Sep;54(9):1989-95 PMID: 23245211 12/19/2012
  • Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes. (Stroupe KT, Tarlov E, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Durazo-Arvizu R, Browning MM, Hynes DM) Pharmacotherapy 2012 Nov;32(11):988-97 PMID: 23108695 10/31/2012
  • Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. (Tarlov E, Stroupe KT, Lee TA, Weichle TW, Zhang QL, Michaelis LC, Ozer H, Browning MM, Hynes DM) Support Care Cancer 2012 Aug;20(8):1649-57 PMID: 21935718 09/22/2011
  • Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. (Le H, Singh S, Shih SJ, Du N, Schnyder S, Loredo GA, Bien C, Michaelis L, Toor A, Diaz MO, Vaughan AT) Genes Chromosomes Cancer 2009 Sep;48(9):806-15 PMID: 19530238 PMCID: PMC2764312 06/17/2009
  • Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. (Nand S, Godwin J, Smith S, Barton K, Michaelis L, Alkan S, Veerappan R, Rychlik K, Germano E, Stiff P) Leuk Lymphoma 2008 Nov;49(11):2141-7 PMID: 19021057 11/21/2008
  • Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. (Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W) Leuk Lymphoma 2008 Mar;49(3):531-7 PMID: 18297531 02/26/2008
  • Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181 PMID: 17502895 05/16/2007
  • Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. (Michaelis LC, Ratain MJ) Clin Cancer Res 2007 Apr 15;13(8):2400-5 PMID: 17438099 04/18/2007
  • Measuring response in a post-RECIST world: from black and white to shades of grey. (Michaelis LC, Ratain MJ) Nat Rev Cancer 2006 05;6(5):409-14 PMID: 16633367 04/25/2006
  • Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? (Stadler WM, Michaelis LC, Ratain MJ) J Clin Oncol 2005 Nov 01;23(31):8124-5; author reply 8125-6 PMID: 16258115 11/01/2005
  • Last update: 05/06/2014
    jenkins-FCD Prod-185 20a1a87aaef305b3f5a3e8bb55f731baa68cadd0